Li Hua Wang1, 2, 7, Xiao Yi Yang1, 7, Xiaohu Zhang1, Kelly Mihalic1, Ying-Xin Fan3, Weihua Xiao1, O M Zack Howard4, Ettore Appella5, Andrew T Maynard1, 6
& William L Farrar21
Basic Research Program, SAIC-Frederick, National Cancer Institute-Frederick, National Institutes of Health, PO Box B, Frederick, Maryland 21702, USA.
2
Cytokine Molecular Mechanisms Section, National Cancer Institute-Frederick, National Institutes of Health, PO Box B, Frederick, Maryland 21702, USA.
3
Division of Therapeutic Protein, Center for Biological Evaluation and Research, Food and Drug Administration, 40 Convent Drive, Bethesda, Maryland 20892, USA.
4
Laboratory of Molecular Immunoregulation, National Cancer Institute-Frederick, National Institutes of Health, PO Box B, Frederick, Maryland 21702, USA.
5
Laboratory of Cell Biology, National Cancer Institute, National Institutes of Health, 40 Convent Drive, Bethesda, Maryland 20892, USA.
6
Present address: AstraZeneca Pharmaceuticals, 1800 Concord Pike, Wilmington, Delaware 19150, USA.
7
These authors contributed equally to this work.
Correspondence should be addressed to Li Hua Wang lhwang@ncifcrf.gov or William L Farrar farrar@ncifcrf.gov
